Privia Health Q2 Revenue Surges 21% to $633M, Raises Full-Year Guidance
PRVA sits 26% above its 52-week low of $19.08.
Summary
Privia Health reported Q2 2026 revenue of $632.6M (+21.4% YoY) and net income of $9.0M (+236.7% YoY), beating estimates. Full-year guidance was raised for all key financial metrics.
Key Events · Earnings and Guidance · PRVA
-
Q2 Revenue Beats Estimates
Revenue reached $632.6 million, up 21.4% year-over-year, driven by growth in implemented providers and value-based care attributed lives.
-
Net Income Triples
Net income surged 236.7% to $9.0 million, or $0.07 per share, compared to $2.7 million in Q2 2025.
-
Adjusted EBITDA Jumps 29%
Adjusted EBITDA rose to $37.4 million, with margin expanding to 28.3% from 25.2% a year ago.
-
Full-Year Guidance Raised
Management lifted its 2026 outlook for practice collections, GAAP revenue, care margin, platform contribution, and adjusted EBITDA, now expecting adjusted EBITDA of $145-$155 million.
Analysis · PRVA · Industrial Applications And Services
A standout quarter saw revenue jump 21% to $632.6 million and net income more than triple to $9 million. The company raised its full-year outlook across all key metrics, signaling confidence in sustained momentum. This performance, against a backdrop of recent insider selling, provides a strong fundamental counterpoint and could shift investor sentiment.
At the time of this filing, PRVA was trading at $24.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3B. The 52-week trading range was $19.08 to $28.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.